Surrogate end points for long-term outcomes in chronic myeloid leukemia.

abstract：:Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

journal_title：Leukemia & lymphoma

authors： Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

更新日期：2002-01-01 00:00:00

abstract：:There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

journal_title：Leukemia & lymphoma

authors： Schultze JL

更新日期：1999-01-01 00:00:00

abstract：:An increasing number of patients are undergoing transplantation procedures or receiving aggressive immunosuppression and chemotherapy. The growing population of immunocompromised hosts has led to a rise in the prevalence of invasive fungal infections (IFIs) due to yeasts and molds. Recent trends suggest that patients ...

journal_title：Leukemia & lymphoma

authors： Chandrasekar P

更新日期：2009-05-01 00:00:00

abstract：:Obesity is a risk factor for mortality and relapse of certain cancers. However, existing evidence for pediatric leukemia is inconsistent. The aim of this systematic review and meta-analysis was to evaluate the association between obesity at diagnosis and pediatric acute leukemia mortality and relapse. This study syste...

journal_title：Leukemia & lymphoma

authors： Amankwah EK,Saenz AM,Hale GA,Brown PA

更新日期：2016-05-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) results from a malignant process that leads to the accumulation in the blood and the bone marrow of myeloid precursor cells characterized by an abnormal behavior and a differentiation arrest. It aroused considerable interest well beyond the hematologic field during the last five year...

journal_title：Leukemia & lymphoma

authors： Cornic M,Chomienne C

更新日期：1995-07-01 00:00:00

abstract：:Nearly ten years of research on the feasibility of specific immunotherapy targeting the junctional regions of BCR-ABL has considerably increased our knowledge of which MHC alleles might present BCR-ABL peptides, yet has failed to provide us with definite proof of appropriate processing of the hybrid oncoprotein into s...

journal_title：Leukemia & lymphoma

authors： Leeksma OC,Kessler JH,Huijbers IJ,Ten Bosch GJ,Melief CJ

更新日期：2000-06-01 00:00:00

abstract：:The Italian Registry for hairy cell leukemia (HCL) has recorded 725 patients with HCL diagnosed over 25 years. We analysed this large series of patients with the aim of providing an evaluation of changes in clinical presentation, impact of initial therapy and modifications in prognostic factors over the period of two ...

journal_title：Leukemia & lymphoma

authors： Frassoldati A,Lamparelli T,Federico M,Annino L,Capnist G,Pagnucco G,Dini E,Resegotti L,Damasio EE,Silingardi V

更新日期：1994-04-01 00:00:00

abstract：:We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

journal_title：Leukemia & lymphoma

authors： Grigg AP

更新日期：2001-08-01 00:00:00

abstract：:Current therapies for the treatment of malignancies are associated with significant limitations to the hematopoietic system since chemotherapy and radiation therapy do not discriminate between normal and malignant cells. Since bone marrow depression occurs at low to midlethal doses of irradiation, approaches to improv...

journal_title：Leukemia & lymphoma

authors： Zucali JR

更新日期：1994-03-01 00:00:00

abstract：:Radioimmunotherapy using (90)Y-ibritumomab tiuxetan has predominantly been used in patients with follicular lymphoma, but little is known about its activity in patients with extranodal marginal zone lymphoma of the mucosa associated lymphoid tissue (MALT). A total of six patients progressing/relapsing following conven...

journal_title：Leukemia & lymphoma

authors： Hoffmann M,Troch M,Eidherr H,Traub-Weidinger T,Jonak C,Muellauer L,Raderer M

更新日期：2011-01-01 00:00:00

abstract：:The purpose of this study was to evaluate the role of 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET-CT) in detecting relapse in patients with primary gastric lymphoma (PGL) post-treatment. Data of 39 previously treated patients with PGL (age: 50.3 ± 13.8 years; male: 24) who ...

journal_title：Leukemia & lymphoma

authors： Sharma P,Suman SK,Singh H,Sharma A,Bal C,Malhotra A,Kumar R

更新日期：2013-05-01 00:00:00

abstract：:Simultaneous occurrence of hairy cell leukemia (HCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (termed CLL) is very rare. Clinical characteristics, pathology and management of these cases have not been well described. We present six patients with CLL and HCL or HCL variant (HCL-v). Of six patients, t...

journal_title：Leukemia & lymphoma

authors： Obiorah IE,Francischetti IMB,Wang HW,Ahn IE,Wang W,Raffeld M,Kreitman RJ,Wiestner A,Calvo KR

更新日期：2020-12-01 00:00:00

abstract：:The clinical features at time of diagnosis of long-term survivors with lymphoma type of adult T-cell leukemia (ATL) were compared with those of short-term survivors. We had 51 Japanese patients with lymphoma type of ATL from 1981 to 1989 who had human T-cell leukemia virus type I (HTLV-I) antibody and monoclonal integ...

journal_title：Leukemia & lymphoma

authors： Shimamot Y,Suga K,Igarashi H,Nishimura J,Nawata H,Yamaguchi M

更新日期：1990-01-01 00:00:00

abstract：:The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen. This was a retrospective, multi-center cohort study of all HIV-1-infected p...

journal_title：Leukemia & lymphoma

authors： Hoffmann C,Wolf E,Wyen C,Fätkenheuer G,Van Lunzen J,Stellbrink HJ,Stoehr A,Plettenberg A,Jaeger H,Noppeney R,Hentrich M,Goekbuget N,Hoelzer D,Horst HA

更新日期：2006-09-01 00:00:00

abstract：:The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplas...

journal_title：Leukemia & lymphoma

authors： Boddu P,Kantarjian H,Garcia-Manero G,Allison J,Sharma P,Daver N

更新日期：2018-04-01 00:00:00

abstract：:Non-Hodgkin lymphoma (NHL) is one of the most common cancers in childhood. The development of chemoresistance in tumor cells is one of the principal causes of treatment failure. This resistance has been associated with different mechanisms, one being the overexpression of anti-apoptotic proteins such as Bcl-xL. It has...

journal_title：Leukemia & lymphoma

authors： Hernandez-Luna MA,Rocha-Zavaleta L,Vega MI,Huerta-Yepez S

更新日期：2013-05-01 00:00:00

abstract：:We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice. In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and...

journal_title：Leukemia & lymphoma

authors： Schultz KR,Gilman AL

更新日期：1997-01-01 00:00:00

abstract：:Human mantle cell lymphoma (MCL) cell lines are scarce and have been only sporadically described and validated, and only a few have been thoroughly molecularly or genetically characterized. We describe here the successful establishment of a new MCL line, PF-1, with typical MCL characteristics. Culturing primary MCL ce...

journal_title：Leukemia & lymphoma

authors： Pham LV,Vang MT,Tamayo AT,Lu G,Challagundla P,Jorgensen JL,Rollo AA,Ou Z,Zhang L,Wang M,Ford RJ

更新日期：2015-01-01 00:00:00

abstract：:Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...

journal_title：Leukemia & lymphoma

authors： Fillmore GC,Wang Q,Carey MJ,Kim CH,Elenitoba-Johnson KS,Lim MS

更新日期：2005-12-01 00:00:00

abstract：:Immunotherapy in the form of allogeneic stem cell transplantation (SCT) plays an instrumental role in the treatment of acute myeloid leukemia (AML), with non-transplant modalities of immunotherapy including checkpoint blockade now being actively explored. Here, we provide an overview of the graft versus leukemia (GVL)...

journal_title：Leukemia & lymphoma

authors： Knorr DA,Goldberg AD,Stein EM,Tallman MS

更新日期：2019-12-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

journal_title：Leukemia & lymphoma

authors： Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

更新日期：2017-09-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

journal_title：Leukemia & lymphoma

authors： Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

更新日期：2004-08-01 00:00:00

abstract：:Myelofibrosis (MF), including primary, post-essential thrombocythemia and post-polycythemia vera MF, associates with a reduced quality of life and shortened life expectancy. Dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is prominent, even in the absence of the ...

journal_title：Leukemia & lymphoma

authors： Stein BL,Cervantes F,Giles F,Harrison CN,Verstovsek S

更新日期：2015-01-01 00:00:00

abstract：:A patient with primary biliary cirrhosis (PBC) who developed idiopathic myelofibrosis (IM) is reported. The initial diagnosis of PBC was established by liver biopsy, performed after a 2-month history of constitutional symptoms associated with abnormalities of the serum liver enzymes, with typical serum immunological m...

journal_title：Leukemia & lymphoma

authors： Hernández-Boluda JC,Jiménez M,Rosiñol L,Cervantes F

更新日期：2002-03-01 00:00:00

abstract：:A diagnosis of the hypogranular variant of acute promyelocytic leukemia (APLv) may be difficult to establish based on cytomorphology alone. However, the great majority of cases have a classical immunophenotype by flow cytometric immunophenotyping (FCI) (CD13+, CD33+, dim CD64+, HLA-DR-, and CD34-) and a classical enzy...

journal_title：Leukemia & lymphoma

authors： Dunphy CH,Polski JM,Johns G,Evans HL,Gardner LJ

更新日期：2001-06-01 00:00:00

abstract：:Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

journal_title：Leukemia & lymphoma

authors： Goebeler ME,Bargou R

更新日期：2016-05-01 00:00:00

abstract：:Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

journal_title：Leukemia & lymphoma

authors： Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

更新日期：2004-06-01 00:00:00

abstract：:Previous studies on the association of Thymidylate synthase (TYMS) polymorphisms with risk of hematological malignancies have produced conflicting results. The purpose of this meta-analysis was to define the effect of TYMS 5'-untranslated enhanced region (TSER) and 3'-untranslated region (TS3'-UTR) polymorphisms on th...

journal_title：Leukemia & lymphoma

authors： Weng Y,Zhang J,Tang X,Xie X,Chen G

更新日期：2012-07-01 00:00:00

abstract：:The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

journal_title：Leukemia & lymphoma

authors： Brown JR

更新日期：2010-08-01 00:00:00

abstract：:The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of human leukocyte antigen-DR expressed on the majority of B-cell lymphomas and on normal B cells of most individuals. Hu1D10 mediates complement-mediated cytotoxicity, antibody-dependent cell-me...

journal_title：Leukemia & lymphoma

authors： Shi JD,Bullock C,Hall WC,Wescott V,Wang H,Levitt DJ,Klingbeil CK

更新日期：2002-06-01 00:00:00